Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition(s) studied
Investigational drug(s) / intervention(s)
Imeroprubart: Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
Placebo: Matching placebo SC QW for 24 weeks (Period 1)
Study summary
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Eligibility
Primary outcome measure(s)
- Proportion of participants remaining Relapse-free by Week 24 — Baseline, Week 24
Relapse is defined as a worsening (increase) of ≥ 1 point on the adjusted inflammatory neuropathy cause and treatment (aINCAT) score at any time point relative to Period 1 Baseline.
Trial sites (143)
| Facility | City | Region | Status |
|---|---|---|---|
| Site Number - 1612 | Tucson | Arizona | Recruiting |
| Site Number - 1618 | Carlsbad | California | Recruiting |
| Site Number - 1637 | Mission Hills | California | Recruiting |
| Site Number - 1619 | Orange | California | Recruiting |
| Site Number - 1607 | Rancho Mirage | California | Recruiting |
| Site Number -1608 | San Francisco | California | Recruiting |
| Site Number - 1626 | Parker | Colorado | Recruiting |
| Site Number - 1621 | New Haven | Connecticut | Recruiting |
| Site Number - 1630 | Washington D.C. | District of Columbia | Recruiting |
| Site Number - 1601 | Washington D.C. | District of Columbia | Recruiting |
| Site Number - 1603 | Maitland | Florida | Recruiting |
| Site Number - 1606 | Miami | Florida | Recruiting |
| Site Number - 1617 | Ormond Beach | Florida | Recruiting |
| Site Number - 1620 | Port Charlotte | Florida | Recruiting |
| Site Number - 1633 | Rockledge | Florida | Recruiting |
| Site Number - 1632 | Chicago | Illinois | Recruiting |
| Site Number - 1602 | Kansas City | Kansas | Recruiting |
| Site Number - 1611 | Nicholasville | Kentucky | Recruiting |
| Site Number - 1623 | Boston | Massachusetts | Recruiting |
| Site Number - 1625 | Worcester | Massachusetts | Recruiting |
| Site Number - 1629 | Detroit | Michigan | Recruiting |
| Site Number - 1634 | Las Vegas | Nevada | Recruiting |
| Site Number - 1605 | New York | New York | Recruiting |
| Site Number - 1627 | New York | New York | Recruiting |
| Site Number - 1635 | Chapel Hill | North Carolina | Not Yet Recruiting |
| Site Number - 1610 | Charlotte | North Carolina | Recruiting |
| Site Number - 1624 | Canton | Ohio | Not Yet Recruiting |
| Site Number - 1631 | Yukon | Oklahoma | Withdrawn |
| Site Number - 1614 | Portland | Oregon | Recruiting |
| Site Number - 1616 | Philadelphia | Pennsylvania | Recruiting |
| Site Number - 1622 | Houston | Texas | Recruiting |
| Site Number - 1628 | San Antonio | Texas | Recruiting |
| Site Number - 1613 | Milwaukee | Wisconsin | Recruiting |
| Site Number - 5005 | Rosario | Santa Fe Province | Recruiting |
| Site Number - 5002 | Buenos Aires | Argentina | Not Yet Recruiting |
| Site Number - 5006 | Buenos Aires | Argentina | Recruiting |
| Site Number - 5001 | Córdoba | Argentina | Recruiting |
| Site Number - 5003 | Córdoba | Argentina | Recruiting |
| Site Number - 5000 | Rosario | Argentina | Recruiting |
| Site Number - 5100 | Macquarie Park | Australia | Recruiting |
+ 103 more sites — see the full list on the official registry below.
More Immunovant Sciences GmbH trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07032662 on ClinicalTrials.gov ↗ ← All trials in Denmark